Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celgosivir - 60 Degree Pharmaceutical Australia

Drug Profile

Celgosivir - 60 Degree Pharmaceutical Australia

Alternative Names: 6-O-Butanoylcastanospermine; 60P 001; BuCast™; celgosivir hydrochloride; MBI-3253; MDL 28574; MDL 28574A; MX-3253; VIR 222

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer 60 Degrees Pharmaceuticals Australia; Carrus Capital Corporation; Duke-NUS Graduate Medical School Singapore; Singapore General Hospital
  • Class Antivirals; Indolizines; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Dengue
  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 31 Dec 2023 60 Degrees Pharmaceuticals has patent protection for "Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infections" in Australia, Malaysia, Mexico, Singapore
  • 31 Dec 2023 60 Degrees Pharmaceuticals has patent pending for "Methods to treat respiratory infection utilizing castanospermine analogs" in USA
  • 31 Dec 2023 60 Degrees Pharmaceuticals has patent pending for "Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue" in Singapore
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top